Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial | Synapse
September 4, 2017Open Access
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Cancer Research UK, Sarcoma UK, and Clinical Trial Unit Kantonsspital St Gallen.